Vipidia 25 is a hypoglycemic agent, which is used in clinical practice to normalize blood sugar against the background of insulin-independent diabetes. The drug can be used as part of a combination therapy to normalize the control of sugar levels. The drug is available in a convenient dosage form of tablets. Hypoglycemic drug should not be taken in children and pregnant women.
International non-proprietary name
Vipidia 25 is a hypoglycemic agent, which is used in clinical practice to normalize blood sugar against the background of insulin-independent diabetes.
Forms of release and composition
The drug is made in tablet form, containing 25 mg of the active substance - alogliptin benzoate. The core of the tablets is complemented with auxiliary compounds:
- microcrystalline cellulose;
- magnesium stearate;
- croscarmellose sodium;
The core of the tablets is complemented with microcrystalline cellulose.
The surface of the tablets is a film shell consisting of hypromellose, titanium dioxide, macrogol 8000, a yellow dye based on iron oxide. Tablets dosage of 25 mg differ in light red color.
The drug belongs to the class of hypoglycemic agents due to the selective suppression of the activity of dipeptidyl peptidase-4. DPP-4 is a key enzyme involved in the accelerated breakdown of hormonal compounds incretin - enteroglucagon and insulinotropic peptide, dependent on glucose level (HIP).
Hormones from the class of incretins are produced in the intestinal tract. The concentration of chemical compounds increases with the consumption of food. Glucagon-like peptide and HIP enhance insulin synthesis by pancreatic islets of Langerhans. Enteroglucagon simultaneously inhibits glucagon synthesis and inhibits gluconeogenesis in hepatocytes, which increases the plasma concentration of incretins. Aogliptin increases insulin secretion, depending on blood sugar levels.
When taken orally, alogliptin is absorbed into the intestinal wall, from where it diffuses into the bloodstream. Bioavailability of the drug reaches 100%. In the blood vessels of the active substance reaches a maximum plasma concentration within 1-2 hours. There is no accumulation of alogliptin in the tissues.
When taken orally, alogliptin is absorbed into the intestinal wall, from where it diffuses into the bloodstream.
The active compound binds to plasma albumin by 20-30%. At the same time, the medicinal product does not undergo transformation and disintegration in hepatocytes. From 60% to 70% of the drug leaves the body in its original form through the urinary system, 13% of alogliptin is excreted with feces. The half-life is 21 hours.
Indications for use
The drug is prescribed to patients for the treatment of non-insulin-dependent diabetes mellitus type 2 and the normalization of glycemic control against the background of the low effectiveness of diet therapy and physical activity. For adult patients, the drug can be prescribed both as monotherapy and as part of complex treatment with insulin or other hypoglycemic drugs.
The drug is contraindicated for use in the following cases:
- in the presence of tissue hypersensitivity to alogliptin and additional components;
- if the patient is prone to anaphylactoid reactions to DPP-4 inhibitors;
- type 1 diabetes;
- children under 18;
- patients with chronic heart failure;
- severe renal and liver dysfunction;
- pregnant and lactating women.
The drug is not prescribed for diabetic ketoacidosis.
It is recommended that patients with acute pancreatitis be cautious in patients with moderate renal failure. It is necessary to control the state of the organs in combination therapy with sulfonylureas or complex treatment with glitazones, Metformin, Pioglitazone.
How to take Vipidia 25?
Tablets are intended for oral administration. It is recommended to use the drug dosage of 25 mg once a day, regardless of the meal. Units of the drug can not be chewed, because mechanical damage reduces the rate of absorption of alogliptin in the small intestine. Do not take a double dose. The pill missed under any circumstances should be taken as soon as possible.
Nutritionists recommend taking Vipidia tablets after meals when the concentration of sugar in the blood rises. When prescribing a medicine as an additional agent for treatment with Metmorphine or Thiazolidinedione, there is no need to correct the dosage regimen of the latter.
With parallel administration of sulfonylurea derivatives, their dose is reduced to prevent the development of a hypoglycemic state. In connection with the possible risk of hypoglycemia, it is necessary to control the sugar level during therapy with Metformin, pancreatic hormone and Thiazolidinedione along with Vipidia.
Due to the possible risk of hypoglycemia, it is necessary to control the level of sugar in Metformin therapy.
Side effects Vipidii 25
Negative effects on organs and tissues are manifested as a result of an improperly chosen dosing regimen.
Perhaps the development of pain in the epigastric region and ulcerative erosive lesions of the stomach, duodenum. In rare cases, acute pancreatitis may occur.
Disorders of the liver and biliary tract
In the hepatobiliary system, there may be abnormalities in the liver and the development of liver failure.
central nervous system
In some cases, a headache.
Immune system disorders
Against a background of weakened immunity, an infectious lesion of the upper respiratory system and the development of nasopharyngitis are possible.
On the part of the skin
Due to the hypersensitivity of tissues, skin rash or itching may occur. Theoretically, the emergence of Stevens-Johnson syndrome, urticaria, exfoliative diseases of the skin.
In patients prone to the occurrence of anaphylactoid reactions, observed urticaria, angioedema. In severe cases, anaphylactic shock develops.
Influence on ability to operate mechanisms
The drug does not affect the ability to drive vehicles and mechanisms, but when combined therapy with other drugs, you need to be very careful.
Patients with kidney failure of moderate severity need to correct the daily dose of the drug and throughout the whole drug therapy is required to constantly monitor the condition of the organ. In severe course of the pathological process, it is not recommended to prescribe Vipidia, as for patients on hemodialysis or in patients with chronic kidney dysfunction.
In connection with the increased risk of inflammation, it is necessary to inform patients about the possible appearance of pancreatitis.
DPP-4 inhibitors are able to provoke acute inflammation of the pancreas. When evaluating 13 clinical studies when volunteers take 25 mg of Vipidia per day, the likelihood of developing pancreatitis was confirmed in 3 out of 1000 patients. Due to the increased risk of an inflammatory process, it is necessary to inform patients about the possible occurrence of pancreatitis, characterized by the following symptoms:
- regular pain in the epigastric region with irradiation in the back;
- feeling of heaviness in left hypochondrium.
If a patient is suspected to have pancreatitis, it is urgent to stop taking the drug and be examined for the presence of inflammation in the pancreas. When receiving positive results of laboratory studies, medication is not renewed.
In the post-marketing period, there were cases of incorrect work of the liver, followed by dysfunction. Communication with the use of Vipidia was not established during the studies, but during the period of drug treatment, it is recommended that susceptible patients undergo regular examinations to monitor liver function. If, as a result of studies, deviations in the work of an organ with an unknown etiology were found, it is necessary to stop taking the drug and then resume it.
During the period of treatment with a drug predisposed to liver dysfunction, patients are recommended to undergo regular examinations to monitor liver function.
Use during pregnancy and lactation
Clinical studies on the effect of the drug on the body of women during pregnancy has not been conducted. During the experiments on animals, no negative effect of the drug on the organs of the reproductive system of the mother, embryotoxicity or teratogenic effects of Vipidia was recorded. At the same time, for safety reasons, the drug is not prescribed to women during pregnancy (due to the possible risk of a violation of the laying of organs and systems in the process of embryonic development).
Aogliptin is able to be eliminated from the body through the mammary glands, therefore during the period of drug therapy it is recommended to refuse lactation.
Appointment Vipidia 25 children
Due to the lack of information on the effect of the active substance on the growth and development of the human body in childhood and adolescence, the drug is contraindicated for administration to 18 years.
Use in old age
Patients over 60 do not need additional dosage adjustment.
Use in violation of kidney function
In the presence of mild renal failure on the background of creatinine clearance (Cl) from 50 to 70 ml / min, no additional changes are made to the dosing regimen. With Cl from 29 to 49 ml / min it is necessary to reduce the daily rate to 12.5 mg for a single dose.
In the presence of mild renal failure on the background of creatinine clearance (Cl) from 50 to 70 ml / min, no additional changes are made to the dosing regimen.
With severe renal dysfunction (Cl reaches less than 29 ml / min), the drug is prohibited.
Overdose Vipidii 25
During clinical studies, the maximum permissible dosage was established - 800 mg per day in healthy patients, and 400 mg per day for patients with non-insulin-dependent diabetes when treated with the drug for 14 days. This exceeds the standard dosage of 32 and 16 times, respectively. The clinical picture of an overdose has not been recorded.
With drug abuse, it is theoretically possible to increase the frequency of development or exacerbation of side effects. When expressed negative reactions, it is necessary to conduct a gastric lavage. In stationary conditions, symptomatic therapy is carried out. Within 3 hours of hemodialysis, only 7% of the accepted dose can be withdrawn, so it is ineffective.
Interaction with other drugs
The drug did not exert pharmacological interactions with the simultaneous appointment of Vipidia with other drugs. The drug did not inhibit the activity of cytochrome P450 isoenzymes, monooxygenase 2C9. Does not interact with p-glycoprotein substrates. Aogliptin in the course of pharmaceutical research did not affect changes in the level of caffeine, warfarin, dextromethorphan, oral contraceptives in plasma.
The drug does not affect changes in the level of dextromethorphan in the body.
Compatibility with alcohol
During the period of treatment with a medicine it is forbidden to drink alcohol. Ethanol contained in alcohol products can cause fatty degeneration of the liver due to toxic effects on hepatocytes. When taking Vipidii toxic effect on the hepatobiliary system increases. Ethyl alcohol causes depression of the central nervous system, impairs blood circulation and has a diuretic effect. As a result of the effect of alcohol on the body, the therapeutic effect of the drug is reduced.
To drug substitutes with similar pharmaceutical properties and chemical structure of the active substance, include:
The synonym is chosen by the attending physician depending on the indicators of the concentration of sugar in the blood and the general condition of the patient. Replacement is made only in the absence of a therapeutic effect or against the background of pronounced adverse reactions.
Pharmacy vacation terms
The drug is not sold without a medical prescription.
Can I buy without a prescription?
Improper dosing of the drug can cause hypoglycemia or hyperglycemia. Hypoglycemic coma may develop, so free selling for patient safety is limited.
Price on Vipidia 25
The average cost of tablets is 1100 rubles.
Drug storage conditions
It is recommended to keep Vipidia at temperatures up to + 25 ° C in a place with a low coefficient of humidity, located far from the action of sunlight.
Takeda Island Limited, Ireland.
Analogue of the drug is Ongliz.
Reviews of Vipidia 25
On online forums, there are positive comments from pharmacists and recommendations on the use of the drug.
Anastasia Sivorova, endocrinologist, Astrakhan.
Effective remedy in the fight against diabetes mellitus type 2. Well tolerated by patients. In clinical practice, did not meet hypoglycemia. Tablets need to be taken 1 time per day without careful calculation of the dosage. Hypoglycemic agent from the new generation, therefore, does not contribute to an increase in body weight. The functional activity of the beta cells of the pancreas is preserved.
Alexey Barredo, endocrinologist, Arkhangelsk.
I liked that with long-term use of the drug, negative manifestations do not develop. The therapeutic effect has a mild hypoglycemic effect, but does not become visible immediately. It is convenient to take - once a day. Good value for money. Does not cause patients allergic reactions.
An analogue of the drug is Januvia.
Gavriil Krasilnikov, 34 years old, Ryazan.
I take Vipidia in a dose of 25 mg for 2 years together with 500 mg of Metformin in the morning after a meal. At first I used Insulin according to the 10 + 10 + 8 scheme. Did not help effectively reduce sugar. The action of the pills is long.Only after 3 months, the sugar began to fall, but after six months, the glucose dropped from 12 to the level of 4.5-5.5. Continues to keep within 5.5. I liked that weight decreased: from 114 to 98 kg with height of 180 cm. But all recommendations from the instructions should be followed.
Ekaterina Gorshkova, 25 years old, Krasnodar.
The mother has type 2 diabetes. The doctor prescribed Maninil, but he did not fit. Sugar did not decrease and state of health worsened on the background of heart problems. Replaced with Vipidia tablets. Take conveniently - 1 time per day. Sugar declined not sharply, but gradually, but the main thing is that mom feels well. The only drawback - a negative effect on the liver.